RecruitingPhase 1NCT06530966

Phase I Study of ICP-332 in Healthy Subjects

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-332 in Healthy Subjects

Sponsor

InnoCare Pharma Inc.

Enrollment

24 participants

Start Date

Jul 23, 2024

Study Type

INTERVENTIONAL

Conditions

Healthy Subjects

Summary

A multiple ascending dose phase I study of ICP-332 in healthy subjects

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Inclusion Criteria3

Voluntarily sign the informed consent form
Body mass index (BMI) of ≥ 18.5 kg/m2 and < 30 kg/m2
Male or infertile female subjects who are between 18-55 years old (inclusive)

Exclusion Criteria4

Significant current or past acute or chronic disease or condition.
A history of tuberculosis or current active/latent infection.
With a history of drug or food allergy, or allergy to any of the composition components of the study drug, or allergic disease.
Subjects with clinically significant abnormalities in the screening examinations.

Interested in this trial?

Get notified about updates and connect with the research team.